Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Gallbladder Neoplasms 1

Interventions

fludarabine phosphate 25Cyclophosphamide 24Peripheral Blood Stem Cell Transplantation 23Busulfan 17Tacrolimus 15Methotrexate 13Cyclosporine 13ruxolitinib 12Whole-Body Irradiation 12Mycophenolic Acid 12Antilymphocyte Serum 11Filgrastim 8Decitabine 7fludarabine 6Etoposide 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6peginterferon alfa-2a 5Radiotherapy 5Methylprednisolone 5Cytarabine 5Carboplatin 5Prednisone 4Melphalan 4Biopsy 4Aspirin 4givinostat hydrochloride 3givinostat 3bomedemstat 3anagrelide 3Topotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thrombocythemia, Essential × Mutation × Clear all
NCT06923670 2025-05-15

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase NA Not yet recruiting
496 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡